EDITOR'S NOTE
ER-positive, tamoxifen-nonresponsive breast cancer is a bad disease
Neil Love, MD

INTERVIEW  
Kevin R Fox, MD
Director, Rena Rowan Breast Center
Associate Professor of Medicine
University of Pennsylvania
Cancer Center
Philadelphia, Pennsylvania
- Select publications

William J Gradishar, MD
Director, Breast Medical Oncology
Associate Professor of Medicine
Robert H Lurie Comprehensive
Cancer Center
Northwestern University Feinberg
School of Medicine
Chicago, Illinois
- Select publications

Professor John F R Robertson,
MB, ChB, BSc, MD

Professor of Surgery
Head of Academic Division of Breast Surgery
University of Nottingham City Hospital
Nottingham, United Kingdom
- Select publications

Patrick I Borgen, MD
Professor of Surgery
Weill Medical College of Cornell University
Chief, Breast Service
Department of Surgery
Memorial Sloan-Kettering
Cancer Center
New York, New York
- Select publications

   
   

Highlights from a Miami Breast Cancer Conference Tumor
Panel Discussion on Adjuvant Systemic Therapy


Adjuvant Trastuzumab for Patients with HER2-Positive Disease

- Select publications

Adjuvant Endocrine Therapy for Patients with ER- and/or PR-Positive Disease
- Select publications

Selection and Schedule of Adjuvant Chemotherapy
- Select publications

Joyce O’Shaughnessy, MD
Co-Director, Breast Cancer
Research Program
Baylor-Charles A Sammons
Cancer Center
US Oncology
Dallas, Texas

Peter M Ravdin, MD, PhD
Clinical Professor of Medicine
The University of Texas
Health Science Center at San Antonio
San Antonio, Texas

Richard Sainsbury, MD
Senior Lecturer, Department of Surgery
University College London
London, United Kingdom

Steven Shak, MD
Chief Medical Officer
Genomic Health Inc
Redwood City, California

George W Sledge Jr, MD
Professor of Medicine
Ballve-Lantero Professor of Oncology
Indiana University Medical Center
Indianapolis, Indiana

   

Editor's Office
Faculty Disclosures

Breast Cancer Update:
A CME Audio Series and Activity